Stock Analysis

BioNTech SE American Depositary ShareBNTX

Price:$87.71Market Closed-2.76%at last close

Sector: Healthcare

AnalystsStrong Buy27 analysts

Mkt Cap 22.09BROE -9.1%

Low $83.89$87.71High $119.34

Price is 11% of the way from the year's low to its high.

PMP Verdict

Insufficient financial data

No financial statements on file for this ticker — fundamental scores are not computed.

Market context

-2.8% today· Z 0.9σ

What's happening with BNTX

Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put — Yahoo, 12h agoLast big move: -4.7% on 2026-10-13

Risk Flags

⚠Interest coverage -1.4× — thin debt cushion

About BioNTech SE American Depositary Share

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. Show more

The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Employees: 7,807 · Website ↗

Price History

Weekly Candlestick Chart — up to 5Y

Key Metrics

Financial snapshot · Tap any metric for its definition and grade

Valuation

42D+

P/E (TTM)—

Price / TTM EPS (own statements)

P/FCF18.2xB

Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative

FCF Yield5.5%A

Grade A: ValueInverse of Finnhub P/FCF (own TTM FCF unavailable)

P/S (TTM)7.59xC

Grade C: ExpensivePrice / TTM Revenue (own statements)

EV/EBITDA13.1xB

Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral

EV/Sales4.0xB

Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple

Forward P/E—

Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth

P/B Ratio1.18xA

Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks

PEG Ratio-0.03A

Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)

Dividend Yield—

TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress

Payout Ratio17.6%A

Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable

Profitability

ROIC—

NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat

ROE-9.1%D

Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks

ROA-8.0%D

Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit

Net Margin-63.6%D

Grade D: LowNet Income / Revenue

Operating Margin—

TTM EBIT / TTM Revenue

Gross Margin79.2%A

Grade A: PremiumGross Profit / Revenue

FCF Margin—

FCF / Revenue

True FCF Margin—

TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost

Growth

Revenue CAGR—

Compound annual revenue growth (up to 5Y depending on data availability)

Net Income CAGR—

Compound annual net income growth (up to 5Y depending on data availability)

EPS CAGR (5Y)—

Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0

Implied EPS Growth—

Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth

Dilution (5Y)—

Share count change over 5Y

SBC / Net Income—

Stock-based comp/Net income. >30% = dilution risk

SBC / Revenue—

TTM stock-based comp / TTM Revenue

Financial Health

25E

Altman Z-Score—

Bankruptcy risk. >3 Safe, <1.8 Distress

Current Ratio7.85xA

Grade A: HighCurrent Assets/Liabilities

Quick Ratio7.80xA

Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory

Interest Coverage-1.4xD

Grade D: RiskyEBIT/Interest. >10 Strong

Debt Repayment—

Years to repay net debt via FCF

Net Debt/EBIT—

Leverage. <2x Low, >4x High

Debt/Equity0.02xA

Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.

Cash / Debt—

Cash covers how much of total debt. >1 = could repay all debt from cash

Quality

Piotroski F-Score—

Financial strength 0–9. >7 Strong

Beneish M-Score—

Earnings manipulation risk. < -2.22 Safe

FCF Conversion—

FCF / Net Income

Margin Stability—

EBIT margin std deviation. Lower = stable

Capex / Revenue—

TTM CapEx / TTM Revenue — high % = capital-hungry business

Asset Turnover0.13xD

Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales

Insider Transactions

SEC Form 4 · 8 records

Open-market · 90dBuy —Sell $47.5M (15)Net open-market selling

P/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.

Recent insider transactions
Trade date	Insider	Transaction	Shares	Filed
2026-10-09 Sahin Ugur Filed 2026-10-09	Sahin Ugur	SellOpen market sale	-36209	2026-10-09
2026-10-08 Sahin Ugur Filed 2026-10-09	Sahin Ugur	SellOpen market sale	-27000	2026-10-09
2026-10-07 Sahin Ugur Filed 2026-10-07	Sahin Ugur	SellOpen market sale	-24000	2026-10-07
2026-10-06 Sahin Ugur Filed 2026-10-06	Sahin Ugur	SellOpen market sale	-21000	2026-10-06
2026-10-05 Sahin Ugur Filed 2026-10-06	Sahin Ugur	SellOpen market sale	-72000	2026-10-06

Show 3 more filings

Additional recent insider transactions
Trade date	Insider	Transaction	Shares	Filed
2026-10-02 Sahin Ugur Filed 2026-10-02	Sahin Ugur	SellOpen market sale	-17000	2026-10-02
2026-10-01 Sahin Ugur Filed 2026-10-02	Sahin Ugur	SellOpen market sale	-17000	2026-10-02
2026-09-28 Sahin Ugur Filed 2026-09-28	Sahin Ugur	SellOpen market sale	-34000	2026-09-28

More metrics — Moat, Per Share, Balance Sheet, Market

Moat

ROIC >12% Years—

Share of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability

Gross Margin (Med.)—

Median annual gross margin across available fiscal years — pricing-power durability

FCF-Positive Years—

Share of completed fiscal years with positive free cash flow

Net Margin Floor—

Weakest annual net margin across completed fiscal years — recession/downcycle resilience

Per Share

EPS (TTM)—

TTM net income per share (Finnhub fallback)

Cash / Share$58.83

Cash & short-term investments per share (Finnhub)

Book Value / Share$70.69

Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks

Balance Sheet

Total Debt—

Total debt obligations (short + long term)

Cash & Equiv.—

Cash and short-term investments

Net Debt—

Total Debt minus Cash. Negative = Net Cash position

Total Equity—

Shareholders' equity (book value)

Asset / Liability—

Total Assets / Total Liabilities

Market

Market Cap$22.09B

Current Market Capitalization

Beta1.33C

Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings

How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.

Ratio snapshot Oct 17, 2026

See how BNTX ranks on the Capex Tracker — top 50 capital spenders compared.

Recent Market Moves

See all BNTX moves →

Date	Session	Price	Move	Z-Score
Oct 13	Pre-market	91.30	-4.74%	-2.29
Oct 13	Regular	89.56	-6.55%	-3.20
Oct 13	After-hours	89.40	-6.72%	-3.29
Oct 9	Regular	97.02	+5.39%	3.01
Oct 9	After-hours	97.20	+5.58%	3.11

Frequently Asked Questions about BNTX

What is the current BioNTech SE American Depositary Share (BNTX) stock price?

BNTX is trading at $87.71 at the last market close, down 2.76% on the session. PreMarketPrice tracks BNTX pre-market, intraday and after-hours prices.

Is BNTX stock a buy right now?

PreMarketPrice's quantitative model rates BioNTech SE American Depositary Share's financial health at 25/100. This is a data-driven snapshot of fundamentals, not investment advice.

Is BNTX stock overvalued?

BioNTech SE American Depositary Share trades at a trailing P/E of n/a and our valuation score rates it 42/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.

When does BioNTech SE American Depositary Share report earnings?

No confirmed earnings date is currently scheduled for BNTX. The Earnings section lists recent reports and updates as dates are announced.

What sector does BioNTech SE American Depositary Share operate in?

BioNTech SE American Depositary Share operates in the Healthcare sector. The Related Stocks section lists sector peers for comparison.

What does BioNTech SE American Depositary Share do?

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid.

About BioNTech SE American Depositary Share (BNTX) Stock

BioNTech SE American Depositary Share (BNTX) is a US-listed stock operating in the Healthcare sector. As of the latest update, BioNTech SE American Depositary Share is trading at $87.71, down 2.76% on the day with a market capitalization of $22.1 billion. The financial health score for BNTX is 25/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BNTX stock.

BNTX Stock Analysis & Key Metrics

On PreMarketPrice, you can track BioNTech SE American Depositary Share (BNTX) across multiple dimensions:

Pre-market price & movement: Real-time BNTX stock price with percentage change, updated continuously during pre-market and regular trading hours.
Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BNTX with trend analysis and normalized valuation multiples.
Financial statements: Revenue, net income, assets, liabilities, and equity for BioNTech SE American Depositary Share across multiple reporting periods.
Financial health score: A composite score of 25/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BNTX.
Sector peers: Compare BNTX against 2 other healthcare stocks on key financial metrics.

Is BNTX a Good Stock to Buy?

This page provides data-driven analysis to help you evaluate BioNTech SE American Depositary Share (BNTX) as an investment. The financial health score of 25/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.

Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.BioNTech SE American Depositary Share (BNTX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.

BioNTech SE American Depositary Share (BNTX) Premarket Movers →BioNTech SE American Depositary Share (BNTX) Valuation & P/E History →BioNTech SE American Depositary Share (BNTX) Financial Statements →BioNTech SE American Depositary Share (BNTX) Unusual Moves & Catalyst History — GainersLosers →BNTX Stock CVThe whole company on one page — stockcv.com Writing about BNTX? Embed this CV card on your site →

Related opportunities

Moving today in Healthcare

NVAX-13.0%Z -2.4σ MRNA-8.8%Z -2.1σ

All movers today →Healthcare sector overview →